Allarity Therapeutics, Inc. (ALLR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -13 | -11 | ||||||
| Net profit | $m | -7 | -27 | -16 | -12 | -25 | -11 | -12 | -12 |
| EPS reported | $ | -0.78 | -0.78 | ||||||
| Operating cashflow per share | $ | -1.03 | -0.86 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -1.03 | -0.87 | ||||||
| Free cash flow | $m | -15 | -14 | ||||||
| Net debt | $m | -13 | 5 | ||||||
| Book value equity | $m | 10 | 4 | ||||||
| Book value per share | $ | 0.68 | 0.22 | ||||||
| Number of shares | m | 14.38 | 15.91 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.58 | 4.39 | ||||||
| P/S LTM | x | 48.53 | 45.01 | ||||||
| P/FCF LTM | x | -1.05 | -1.13 | ||||||
| EV/EBITDA LTM | x | -0.20 | -0.20 | ||||||
| EV/Sales LTM | x | 7.01 | 80.86 | ||||||
| Earnings Yield LTM | % | -72.32% | -54.59% | ||||||
| FCF Yield | % | -95.48% | -88.75% | ||||||
| Quality | |||||||||
| ROE | % | -114.28% | -152.77% | ||||||
| ROIC | % | -1.12% | -41.81% | ||||||
| Operating margin | % | -39.39% | -31.29% | ||||||
| Gross margin | % | +100.00% | +1.08% | ||||||
| FCF/Sales | % | -4633.8% | -3994.8% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -10.59 | -0.62 | ||||||
| Net Debt/EBITDA | x | 1.20 | -0.48 | ||||||
| EBIT/Net interest | x | -68.14 | -10.15 | ||||||
| Net debt/market cap | % | +9.02% | +98.64% | ||||||
| Net debt/Equity | x | -1.35 | 1.50 | ||||||
| Gross debt/equity | x | 0.14 | 6.30 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Allarity Therapeutics, Inc. (ALLR)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free